Testing a liver pump with standard chemo for colorectal cancer that spread to the liver
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a special chemotherapy pump implanted in your liver (hepatic arterial infusion) to standard chemotherapy works better than standard chemotherapy alone for people whose colorectal cancer has spread only to the liver and cannot be removed by surgery. The pump delivers high doses of chemo directly to the liver to shrink tumors and possibly control the disease longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your colorectal cancer has spread only to your liver, not to other organs or lymph nodes outside the liver (with a few exceptions).
- You have had at least one line of chemotherapy for your colorectal cancer, and you meet specific cycle counts or you developed liver metastases within 12 months after finishing chemo for early-stage colorectal cancer.
- Your liver tumor cannot be removed surgically at the time of joining, and your liver tumor burden is less than 70% of your liver volume.
- You have not had radiation to the liver, embolization procedures, or prior treatment with a liver pump.
- Your cancer is not microsatellite instability-high (MSI-H), and you are in good general health (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a strong chemotherapy combination given directly into the liver's blood supply (called HAIC) for people whose colorectal cancer has spread only to the liver and cannot be removed with surgery yet. The goal is to shrink the liver tumors enough so they can be surgically removed.
This trial tests a special type of chemotherapy (hepatic artery infusion) for people with cancers that have spread to the liver, such as colorectal cancer or bile duct cancer (intrahepatic cholangiocarcinoma). It studies whether delivering this treatment partly at a community center and partly at a university hospital is safe and feasible.
This trial tests a treatment approach where you receive chemotherapy directly into your liver through a surgically placed pump, combined with standard systemic chemotherapy (given through a vein). The goal is to shrink liver tumors enough so they can be removed later with surgery. It is for people whose colorectal cancer has spread only to the liver and has not been treated before.
This phase 2 study tests a liver-targeted medicine delivered through a special implanted pump, combined with standard chemo, for cancers that spread mainly to the liver. It may help control tumor growth in the liver and improve outcomes compared with standard treatment alone.
This Phase 3 trial tests different ways to deliver chemotherapy for colon cancer that has spread only to the liver (with limited possible tiny lung spots). It looks at whether the treatment plan improves outcomes compared with another chemotherapy approach, using oxaliplatin and LV5FU2 (with or without irinotecan) plus an added targeted medicine.
This trial is testing a new way to give the chemotherapy drug paclitaxel directly into the liver (through a tiny tube) along with standard systemic treatment for people whose colorectal cancer has spread only to the liver and cannot be surgically removed. The goal is to see if this targeted approach works better than standard treatment alone.
Hear when a new Metastatic Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.